Augmentation in treatment-resistant depression

Drugs of the Future

Volumn 31, Issue 12, 2006, Pages 1069-1081

  McIntyre, J ^a   Moral, Ma Àngels ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; BUSPIRONE; CITALOPRAM; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; LORAZEPAM; MECAMYLAMINE; MEMANTINE; METHYLPHENIDATE; MODAFINIL; NORTRIPTYLINE; OLANZAPINE; OROS; PHENYTOIN; PINDOLOL; PLACEBO; PRAMIPEXOLE; RISPERIDONE; ROPINIROLE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TESTOSTERONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; ZIPRASIDONE;

ADD ON THERAPY; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DAYTIME SOMNOLENCE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATIGUE; HEADACHE; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; INCREASED APPETITE; LOW DRUG DOSE; MAJOR DEPRESSION; META ANALYSIS; METABOLIC SYNDROME X; MONOTHERAPY; NONHUMAN; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION; WEIGHT GAIN; XEROSTOMIA;

EID: 33847082500     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.12.1049172     Document Type: Review

References (88)

1. Prous Science Disease Briefing: Depression, online publication.
2. Souery, D., Papakostas, G.I., Trivedi, M.H. Treatment-resistant depression. J Clin Psychiatry 2006, 67(Suppl. 6): 16-22.
3. Thase, M.E. Therapeutic alternatives for difficult-to-treat depression: A narrative review of the state of the evidence. CNS Spectr 2004, 9(11): 808-21.
4. Keller, M.B. Issues in treatment-resistant depression. J Clin Psychiatry 2005, 66(Suppl. 8): 5-12.
5. DeBattista, C. Augmentation and combination strategies for depression. J Psychopharmacol 2006, 20(3, Suppl.): 11-8.
6. Fava, M., Rush, A.J., Trivedi, M.H. et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am 2003, 26(2): 457-94.
7. Bauer, M., Adli, M., Baethge, C., Berghofer, A., Sasse, J., Heinz, A., Bschor, T. Lithium augmentation therapy in refractory depression: Clinical evidence and neurobiological mechanisms. Can J Psychiatry 2003, 48(7): 440-8.
8. Nierenberg, A.A., Papakostas, G.I., Petersen, T. et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 2003, 23(1): 92-5.
9. Fava, M., Alpert, J., Nierenberg, A. et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002, 22(4): 379-87.
10. Bschor, T., Bauer, M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 2006, 12(23): 2985-92.
11. Joffe, R.T., Sokolov, S.T. Thyroid hormone treatment of primary unipolar depression: A review. Int J Neuropsychopharmacol 2000, 3(2): 143-7.
12. Aronson, R., Offman, H.J., Joffe, R.T., Naylor, C.D. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996, 53(9): 842-8.
13. Agid, O., Lerer, B. Algorithm-based treatment of major depression in an outpatient clinic: Clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Int J Neuropsychopharmacol 2003, 6(1): 41-9.
14. Iosifescu, D.V., Nierenberg, A.A., Mischoulon, D. et al. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry 2005, 66(8): 1038-42.
15. Abraham, G., Milev, R., Stuart, L.J. T3 augmentation of SSRI resistant depression. J Affect Disord 2006, 91(2-3): 211-5.
16. Nierenberg, A.A., Fava, M., Trivedi, M.H. et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report. Am J Psychiatry 2006, 163(9): 1519-30.
17. Lifschytz, T., Gur, E., Lerer, B., Newman, M.E. Effects of triiodothyronine and fluoxetine on 5-HT1A and 5-HT1B autoreceptor activity in rat brain: Regional differences. J Neurosci Meth 2004, 140(1-2): 133-9.
18. Shelton, R.C., Tollefson, G.D., Tohen, M. et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001, 158(1): 131-4.
19. Shelton, R.C., Williamson, D.J., Corya, S.A. et al. Olanzapine/ fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005, 66(10): 1289-97.
20. Thase, M.E., Corya, S.A., Osuntokun, O. et al. Olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. 59th Annu Meet Am Psychiatr Assoc (May 20-26, Toronto) 2006, Abst NR601.
21. Olanzapine augmentation therapy in treatment-resistant depression: A double-blind placebo-controlled trial (NCT00273624). ClinicalTrials.gov Web site 2006.
22. Zhang, W., Perry, K.W., Wong, D.T., Potts, B.D., Bao, J., Tollefson, G.D., Bymaster, F.P. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000, 23(3): 250-62.
23. Sharpley, A.L., Attenburrow, M.E., Hafizi, S., Cowen, P.J. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry 2005, 66(4): 450-4.
24. Amargos-Bosch, M., Artigas, F., Adell, A. Effects of acute olanzapine after sustained fluoxetine on extracellular monoamine levels in the rat medial prefrontal cortex. Eur J Pharmacol 2005, 516(3): 235-8.
25. Maragnoli, M.E., Fumagalli, F., Gennarelli, M., Racagni, G., Riva, M.A. Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol Psychiatry 2004, 55(11): 1095-102.
26. Papakostas, G.I., Petersen, T.J., Kinrys, G. et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005, 66(10): 1326-30.
27. Simon, J.S., Nemeroff, C.B. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005, 66(10): 1216-20.
28. Pae, C.-U., Patkar, A., Candace, A. et al. Aripiprazole augmentation for patients with major depressive disorder who failed to respond to antidepressani therapy. 159th Annu Meet Am Psychiatr Assoc (May 20-26, Toronto) 2006, Abst NR565.
29. Barbee, J.G., Conrad, E.J., Jamhour, N.J. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry 2004, 16(4): 189-94.
30. Ability as an adjunctive treatment for refractory depression (NCT00220636). ClinicalTrials.gov Web site 2006.
31. Aripiprazole augmentation therapy in treatment-resistant depression (NCT00276978). ClinicalTrials.gov Web site 2006.
32. A long-term study of aripiprazole in patients with major depressive disorder (NCT00095745). ClinicalTrials.gov Web site 2006.
33. A study of adjunctive aripiprazole in patients with major depressive disorder (NCT00095758). ClinicalTrials.gov Web site 2006
34. Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., Altar, C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002, 441(3): 137-40.
35. Rapaport, M.H., Gharabawi, G.M., Canuso, C.M. et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006, 31(11): 2505-13.
36. Risperidone augmentation therapy in patients who have failed or only partially responded to a trial of antidepressant (NCT00174577). ClinicalTrials.gov Web site 2006.
37. Risperidone vs bupropion ER augmentation of SSRIs in treatment-resistant depression (NCT00179244). ClinicalTrials.gov Web site 2006.
38. Huang, M., Ichiwaka, J., Li, Z., Dai, J., Meltzer, H.Y. Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology (Berl) 2006, 185(3): 274-81.
39. Dremencov, E., El Mansari, M., Blier, P. Noradrenergic augmentation of escitalopram response by risperidone: Electrophysiologic studies in the rat brain. Biol Psychiatry 2006, Epub ahead of print.
40. Papakostas, G.I., Petersen, T.J., Nierenberg, A.A., Murakami, J.L., Alpert, J.E., Rosenbaum, J.F., Fava, M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004, 65(2): 217-21.
41. Dimitriou, E.C., Dimitriou, C.E. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 1998, 18(6): 465-9.
42. Landen, M., Bjorling, G., Agren, H., Fahlen, T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998, 59(12): 664-8.
43. Appelberg, B.G., Syvalahti, E.K., Koskinen, T.E., Mehtonen, O.P., Muhonen, T.T., Naukkarinen, H.H. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: Results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001, 62(6): 448-52.
44. Trivedi, M.H., Fava, M., Wisniewski, S.R. et al. Medication augmentation after the failure of SSRIs for depression. New Engl J Med 2006, 354(12): 1243-52.
45. Sim-Selley, L.J., Vogt, L.J., Xiao, R., Childers, S.R., Selley, D.E. Region-specific changes in 5-HT(1A) receptor-activated G-proteins in rat brain following chronic buspirone. Eur J Pharmacol 2000, 389(2-3): 147-53.
46. McIntyre, J., Moral, M.A. Spotlight on lamotrigine for depression. Drug News Perspect 2006, 19(7): 427-30.
47. Baloescu, A. et al. Lamotrigine in the treatment of resistant depression. 14th Assoc Eur Psychiatr Congr (March 4-8, Nice) 2006, Abst 093.
48. Gutierrez, R.L., McKercher, R.M., Galea, J., Jamison, K L. Lamotrigine augmentation strategy for patients with treatment-resistant depression. CNS Spectr 2005, 10(10): 800-5.
49. Schindler, F. et al. The LILA-Study: An observational study comparing the efficacy of lithium vs lamotrigine as an augmentation strategy for treatment-resistant depression (TRD). 59th Annu Meet Soc Biol Psychiatry (SOBP) (April 29-May 1, New York) 2004, Abst 140.
50. Rocha, F.L., Hara, C. Lamotrigine augmentation in unipolar depression. Int Clin Psychopharmacol 2003, 18(2): 97-9.
51. Barbee, J.G., Jamhour, N.J. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 2002, 63(8): 737-41.
52. Barbosa, L., Berk, M., Vorster, M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003. 64(4): 403-7.
53. Vinod, K.Y., Subhash, M.N. Lamotrigine induced selective changes in 5-HT(1A) receptor mediated response in rat brain. Neurochem Int 2002, 40(4): 315-9.
54. Bourin, M., Masse, F., Hascoet, M. Evidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming test. J Psychiatry Neurosci 2005, 30(4): 275-82.
55. Huang, C.W., Hsieh, Y.J., Tsai, J.J., Huang, C.C. Effects of lamotrigine on field potentials, propagation, and long-term potentiation in rat prefrontal cortex in multi-electrode recording. J Neurosci Res 2006, 83(6): 1141-50.
56. Phenytoin as an augmentation for SSRI failures (NCT00146237). ClinicalTrials.gov Web site 2006.
57. Romero, L., Bel, N., Artigas, F., de Montigny, C., Blier, P. Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: In vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 1996, 15(4): 349-60.
58. Kinney, G.G., Taber, M.T., Gribkoff, V.K. The augmentation hypothesis for improvement of antidepressant therapy: Is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency? Mol Neurobiol 2000, 21(3): 137-52.
59. Rabiner, E.A., Bhagwagar, Z., Gunn, R.N., Cowen, R.J., Grasby, P.M. Preferential 5-HT1A autoreceptor occupancy by pindolol is attenuated in depressed patients: Effect of treatment or an endophenotype of depression? Neuropsychopharmacology 2004, 29(9): 1688-98.
60. Perry, E.B., Berman, R.M., Sanacora, G., Anand, A., Lynch-Colonese, K., Charney, D.S. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: A double-blind, randomized, controlled trial. J Clin Psychiatry 2004, 65(2): 238-43.
61. Popik, P., Kozela, E., Krawczyk, M. Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram. Br J Pharmacol 2003, 139(6): 1196-202.
62. Nicotinic receptor augmentation of SSRI antidepressants (NCTQ0319319). ClinicalTrials.gov Web site 2006.
63. Lattanzi, L., Dell'Osso, L., Cassano, P et al. Pramipexole in treatment-resistant depression: A 16-week naturalistic study. Bipolar Disord 2002, 4(5): 307-14.
64. Cassano, P., Lattanzi, L., Soldani, F. et al. Pramipexole in treatment-resistant depression: An extended follow-up. Depress Anxiety 2004, 20(3): 131-8.
65. Effectiveness of pramipexole for treatment-resistant depression (NCT00231959). ClinicalTrials.gov Web site 2006.
66. Cassano, P., Lattanzi, L., Fava, M. et al. Ropinirole in treatment-resistant depression: A 16-week pilot study. Can J Psychiatry 2005, 50(6): 357-60.
67. Ropinirole CR as an adjunctive agent in the treatment of major depression (NCT00285727). ClinicalTrials.gov Web site 2006.
68. Masand, P.S. A randomized, double-blind, placebo-controlled, flexible-dose, trial of augmentation with OROS methylphenidate in treatment resistant depression. 159th Annu Meet Am Psychiatr Assoc (May 20-26, Toronto) 2006, Abst NR548.
69. Lavretsky, H., Park, S., Siddarth, P., Kumar, A., Reynolds, C.F. III. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: A double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 2006, 14(2): 181-5.
70. Concerta® (methylphenidate hydrochloride) as add-on therapy in the treatment of adult major depressive disorder (NCT00246233). ClinicalTrials.gov Web site 2006.
71. DeBattista, C., Doghramji, K., Menza, M.A., Rosenthal, M.H., Fieve, R.R. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: A preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003, 64(9): 1057-64.
72. Fava, M., Thase, M.E., DeBattista, C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005, 66(1): 85-93.
73. Thase, M.E., Fava, M., DeBattista, C., Arora, S., Hughes, R.J. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: A 12-week, open-label, extension study. CNS Spectr 2006, 11(2): 93-102.
74. Ferraro, L., Fuxe, K., Agnati, L., Tanganelli, S., Tomasini, M.C., Antonelli, T. Modafinil enhances the increase of extracellular serotonin levels induced by the antidepressant drugs fluoxetine and imipramine: A dual probe microdialysis study in awake rat. Synapse 2005, 55(4): 230-41.
75. Seidman, S.N., Miyazaki, M., Roose, S.P. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: Randomized placebo-controlled clinical trial. J Clin Psychopharmacol 2005, 25(6): 584-8.
76. Pope, H.G. Jr., Cohane, G.H., Kanayama, G., Siegel, A.J., Hudson, J.I. Testosterone gel supplementation for men with refractory depression: A randomized, placebo-controlled trial. Am J Psychiatry 2003, 160(1): 105-11.
77. Orengo, C.A., Fullerton, L., Kunik, M.E. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol 2005, 18(1): 20-4.
78. AndroGel in men with major depression and incomplete response to antidepressant treatment (NCT00304746). ClinicalTrials.gov Web site 2006.
79. Rogoz, Z., Skuza, G., Maj, J., Danysz, W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 2002, 42(8): 1024-30.
80. Skuza, G., Rogoz, Z. The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats. J Physiol Pharmacol 2006, 57(2): 217-29.
81. Memantine augmentation of antidepressants (NCT00344682). ClinicalTrials.gov Web site 2006.
82. VNS Therapy System receives FDA approval for treatment-resistant depression. DailyDrugNews.com July 19, 2005.
83. Treatment-resistant depression registry (NCT00320372). ClinicalTrials.gov Web site 2006.
84. Study comparing outcomes for patients with treatment resistant depression who receive VNS therapy at different doses (NCT00305565). ClinicalTrials.gov Web site 2006.
85. Three new mechanism-of-action studies begin for VNS therapy. DailyDrugNews.com May 26, 2006.
86. Nahas, Z., Marangell, L.B., Husain, M.M. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005, 66(9): 1097-104.
87. George, M.S., Rush, A.J., Marangell, L.B. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005, 58(5): 364-73.
88. Rush, A.J., Sackeim, H.A., Marangell, L.B. et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: A naturalistic study. Biol Psychiatry 2005, 58(5): 355-63.